Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products. Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
27/07/26	ILA 170.40	-1.79%	78,929
24/07/26	ILA 173.50	+2.18%	89,117
22/07/26	ILA 169.80	-1.22%	272,019
21/07/26	ILA 171.90	-5.39%	92,334
20/07/26	ILA 181.70	+5.33%	175,603

Delayed Quote TEL AVIV STOCK EXCHANGE

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 11:13:01 27/07/26 pm AEST			5-day change	1st Jan Change
170.40 ^ILa	-1.79%		-6.22%	-43.31%

23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT

Market Cap	5.93M 0 5.21M 4.85M 4.45M 8.35M 571M 8.48M 57.53M 22.48M 281M 22.27M 21.79M 971M	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.93M 0 5.21M 4.85M 4.45M 8.35M 571M 8.48M 57.53M 22.48M 281M 22.27M 21.79M 971M	EV / Sales 2026 *	4x	EV / Sales 2027 *	2.28x
Free-Float	82.98%	Yield 2026 *	-	Yield 2027 *	-

23/07	Evogene Ltd. and Eleo Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule Pcsk9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	CI
22/07	Evogene, ELEO Collaborating to Develop Oral PCSK9 Inhibitors	MT
11/07	L.I.A. Pure Capital Sends Letter to Evogene	CI
09/07	Evogene Ltd. and Blavatnik Center For Drug Discovery at Tel Aviv University Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	CI
24/06	Evogene Ltd. And Google Cloud Announces Major Milestone In Collaboration Advancing ChemPass AI Toward Autonomous Small Molecule Discovery And Optimization	CI
02/06	Biomica Completes Phase 1 Clinical Study of Bmc128 in Combination with Nivolumab	CI
21/05	Evogene Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
21/05	Evogene Ltd., Q1 2026 Earnings Call, May 20, 2026
20/05	Evogene Ltd files for offering of 2.45 million ordinary shares by selling shareholder SEC filing	RE
19/05	Evogene Ltd.'S Subsidiary Ag Plenus Ltd. and Bayer Ag to Discontinue Their Herbicide Development Project	CI
25/04	Evogene's Casterra unit eyes castor crop growth in Brazil	RE
03/04	Evogene reports receipt of Nasdaq minimum bid price notification	RE
03/04	Evogene Gets Nasdaq Minimum Bid Price Notification	MT

02/10/23	Alliance Global Starts Evogene at Buy With $1.85 Price Target	MT
19/08/23	Lake Street Adjusts Evogene's Price Target to $3 From $2, Keeps Buy Rating	MT
30/07/21	EVOGENE : Aegis Capital Starts Evogene at Buy	MT
01/12/20	EVOGENE : Cantor Fitzgerald Starts Evogene at Overweight With $9 Price Target	MT

Evogene Ltd. Stock

Stocks

EVGN

IL0011050551

Biotechnology & Medical Research

Valuation: Evogene Ltd.

Chart: Evogene Ltd.

Latest news : Evogene Ltd.

Last Transcript: Evogene Ltd.

Analysts' recommendations: Evogene Ltd.

Press Releases: Evogene Ltd.

News in other languages: Evogene Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Evogene Ltd.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

22/07	Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases	PR
08/07	Evogene : and Tel Aviv University’s Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery	PU
02/06	Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica	PR
20/05	Evogene : Q1 2026 Consolidated Financial Statements	PU
20/05	Evogene: Q1 Earnings Snapshot	AQ

1 day	-1.79%
1 week	-6.22%
Current month	+33.54%
1 month	+37.53%
3 months	-28.43%
6 months	-48.77%
Current year	-43.31%

1 week	156	181.8
1 month	116	194.1
Current year	115.1	410
1 year	115.1	478.7
3 years	115.1	3,954
5 years	115.1	10,430
10 years	115.1	33,500

Manager	Title	Age	Since
Ofer Haviv CEO	Chief Executive Officer	60	01/12/2004
Gabi Tarcic PRN	Corporate Officer/Principal	-	-
Polina Ravzin PRN	Corporate Officer/Principal	-	01/01/2022

Director	Title	Age	Since
Ofer Haviv BRD	Director/Board Member	60	-
Leon Recanati BRD	Director/Board Member	77	03/06/2010
Sarit Firon CHM	Chairman	60	01/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/26	Polina Ravzin	Other	Executive/Senior Manager	20,000	0.2294%
18/3/26	Ilia Zhidkov	Other	Chief Technology Officer	57,750	0.6624%
18/3/26	Adrian Percy	Other	Director	11,200	0.1285%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EVOGENE LTD.	-1.79%	-6.22%	-61.17%	-95.57%	5.93M
LONZA GROUP AG	+1.24%	-1.66%	-1.70%	+10.81%	46.86B
REVOLUTION MEDICINES, INC.	+2.68%	+1.65%	+399.22%	+647.65%	40.23B
BEONE MEDICINES AG	+1.43%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+0.62%	+0.87%	+4.46%	-10.31%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+43.00%	27.89B
MEDPACE HOLDINGS, INC.	+0.15%	+11.84%	+34.39%	+134.44%	16.79B
ASCENDIS PHARMA A/S	+1.11%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.21%	-6.41%	+1.71%	+7.15%	13.12B
ICON PUBLIC LIMITED COMPANY	+0.24%	-2.49%	-11.36%	-34.51%	12.7B
Average	+0.89%	+0.80%	+42.46%	+84.83%	24.53B
Weighted average by Cap.	+1.40%	+0.91%	+75.05%	+137.90%

	2026 *	2027 *
Net sales	1.48M 0 1.3M 1.21M 1.11M 2.09M 143M 2.12M 14.39M 5.62M 70.26M 5.57M 5.45M 243M	2.6M 0 2.28M 2.12M 1.95M 3.66M 250M 3.72M 25.22M 9.85M 123M 9.76M 9.55M 426M
Net income	-16.69M -0 -14.66M -13.63M -12.51M -23.5M -1.61B -23.86M -162M -63.23M -790M -62.64M -61.29M -2.73B	-13.92M -0 -12.22M -11.37M -10.43M -19.6M -1.34B -19.9M -135M -52.73M -659M -52.24M -51.11M -2.28B
Net Debt	-	-